A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Oct 2018
Price : $35 *
At a glance
- Drugs Denosumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed
- Indications Bone metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms SPLENDOUR
- 31 Aug 2018 Biomarkers information updated
- 04 May 2018 This trial has been suspended in Germany.
- 19 Feb 2018 Status changed from recruiting to active, no longer recruiting.